Global Work on Microbicide Development

CONRAD provided supplies of the antiretroviral tenofovir (TFV) 1% gel for the CAPRISA 004 Phase IIb clinical trial for HIV prevention in South Africa, which showed TFV 1% gel to be 39% effective in reducing a woman’s risk of becoming infected with HIV during sex. CONRAD is providing TFV 1% gel for international trials to confirm the CAPRISA results, including FACTS 001 which is replicating the CAPRISA 004 trial with a larger number of women at nine South African sites.

Preclinical microbicide development, including screening and identification of promising compounds, development of animal models, bioanalytical method development and validation, and product formulation is ongoing by investigators, collaborators and contractors in Germany, Northern Ireland, England, Switzerland, Scotland and New Zealand.

Learn more about CONRAD’s global efforts on contraceptive development here.